Akebia Therapeutics (AKBA) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AKBA Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$77.29
FV
98.7% undervalued intrinsic discount264
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Akebia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$4.08 |
| 52 Week Low | US$0.88 |
| Beta | 0.35 |
| 1 Month Change | -27.66% |
| 3 Month Change | -13.56% |
| 1 Year Change | -63.96% |
| 3 Year Change | -15.70% |
| 5 Year Change | -70.86% |
| Change since IPO | -96.18% |
Recent News & Updates
Narrative Update • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Analysis Article • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Recent updates
Narrative Update • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Analysis Article • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Narrative Update • May 03
AKBA: Kidney Pipeline Progress Will Drive Future Upside Despite Inventory Headwinds
Narrative Update on Akebia Therapeutics Analysts have reduced Akebia Therapeutics' price target by $1 to $4, citing updated expectations for Vafseo revenue after a new US Renal Care dosing protocol and related channel inventory adjustments. Analyst Commentary Bullish analysts appear focused on how recent pricing and dosing updates feed into the long term opportunity for Vafseo, even as they recalibrate near term expectations.
Narrative Update • Apr 19
AKBA: Renal Dosing Reset And Inventory Shift Will Support Future Profitability
Akebia Therapeutics' consensus analyst price target has shifted lower, with moves such as a cut from $5 to $4 at BTIG and a $2 reduction at Piper Sandler as analysts factor in recent Vafseo revenue shortfalls tied to US Renal Care's updated dosing protocol and related channel inventory effects. Analyst Commentary Bearish analysts are reassessing Akebia Therapeutics after Vafseo revenue recognized in Q4 came in at about US$5m to US$6m, which they link to a new US Renal Care protocol and an estimated US$4.5m to US$5m decrease in channel inventory.
Narrative Update • Apr 05
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics' Street price targets have been trimmed by analysts, with one firm moving from $5 to $4 as they factor in lower than expected Q4 Vafseo revenue tied to a new US Renal Care dosing protocol and related channel inventory reductions. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after trimming price targets.Narrative Update • Mar 22
AKBA: Renal Care Dosing Reset Will Support Stronger Long Term Profitability
Akebia Therapeutics' consensus analyst price target has moved lower to $4 from $5, as analysts factor in recent updates on Vafseo revenue recognition tied to US Renal Care dosing protocols and related channel inventory adjustments. Analyst Commentary Bearish analysts are framing the lower $4 price target as a reflection of execution risk around the Vafseo launch, especially after the new US Renal Care dosing protocol affected how much revenue could be recognized in the quarter.
New Narrative • Mar 13
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Narrative Update • Mar 07
AKBA: Phase 2 Kidney Disease Trial And Dosing Reset Will Drive Upside
Narrative Update Akebia Therapeutics' consensus analyst price target has shifted from about $5 to roughly $4.40, as analysts factor in the recent US Renal Care dosing protocol change and its impact on Vafseo channel inventory and recognized Q4 revenue. Analyst Commentary Recent research updates reflect a mixed read on Akebia Therapeutics, with targets adjusted to roughly US$4, as analysts factor in the new US Renal Care dosing protocol and its effect on Vafseo revenue recognition in Q4.Narrative Update • Feb 21
AKBA: Rare Kidney Pipeline Progress Will Support Stronger Long Term Profitability
Analysts have reduced their Akebia Therapeutics price target by $3, citing a lower fair value estimate, a higher discount rate, and a shift to expectations of declining revenue growth. This is partly offset by a slightly stronger profit margin outlook and a lower assumed future P/E multiple.Narrative Update • Feb 07
AKBA: Phase 2 Kidney Disease Pipeline Progress Will Drive Substantial Upside
Analysts have trimmed their fair value estimate for Akebia Therapeutics from US$5.40 to US$5.00, citing updated assumptions for growth, profitability and a higher future P/E multiple reflected in recent Street research, including the lowered Piper Sandler price target. Analyst Commentary Recent research around Akebia Therapeutics has focused on how updated growth and profitability assumptions feed into valuation, including the trimmed fair value estimate and a reset price target.Narrative Update • Jan 24
AKBA: Rare Kidney Disease Pipeline Progress Will Drive Future Upside
Analysts now set their price target for Akebia Therapeutics at US$6.00, unchanged from the prior US$6.00. This reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work.Narrative Update • Jan 10
AKBA: Rare Kidney Pipeline And Anemia Data Will Support Future Upside
Analysts have adjusted their price target on Akebia Therapeutics to US$6.00 from US$6.00, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and a slightly higher future P/E multiple. What's in the News Akebia dosed the first patient in a Phase 2 randomized, double blind, placebo controlled trial of praliciguat for biopsy confirmed focal segmental glomerulosclerosis.Narrative Update • Dec 26
AKBA: Rare Kidney Pipeline Progress Will Drive Future Share Upside
Analysts have nudged their price target for Akebia Therapeutics slightly higher to 6.00 dollars per share from 6.00 dollars previously, reflecting modestly improved long term assumptions around revenue growth, profit margins, and the companys risk profile. What's in the News Akebia has initiated Phase 2 clinical development of praliciguat for focal segmental glomerulosclerosis, triggering an expected 1.0 million dollar regulatory milestone payment to Cyclerion when the first patient is dosed, anticipated in 2026 (Key Developments).Narrative Update • Dec 12
AKBA: Rare Kidney Franchise Will Drive Future Share Upside Despite Higher Risk
Analysts have reduced their fair value estimate for Akebia Therapeutics from 10.00 dollars to 6.00 dollars, citing a higher perceived risk profile. This is reflected in an increased discount rate and a lower future earnings multiple, even as long term revenue growth and margin expectations edge higher.Narrative Update • Nov 28
AKBA: European Partnership And Clinical Data Will Drive Substantial Upside
Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth. What's in the News Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe.Narrative Update • Nov 13
AKBA: Broad U.S. Launch In 2025 Will Drive Upside Potential
Analysts have lowered their price target for Akebia Therapeutics from $6.80 to $5.50, citing moderated expectations for revenue growth and profitability. What's in the News Akebia Therapeutics presented a post-hoc win odds analysis from the Phase 3 INNO2VATE trials of vadadustat, showing favorable effects of Vafseo compared to darbepoetin alfa on death or hospitalization in dialysis patients.Analysis Article • Nov 04
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Unfortunately for some shareholders, the Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) share price has dived 25% in the...Narrative Update • Oct 30
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.Analysis Article • Aug 10
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
NasdaqCM:AKBA 1 Year Share Price vs Fair Value Explore Akebia Therapeutics's Fair Values from the Community and select...Analysis Article • Jun 18
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...Analysis Article • May 10
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) had a good week, as its shares rose 4.1% to close at US$2.55...Analysis Article • May 04
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...
New Narrative • Apr 28
Vafseo And VALOR Study Will Open New Treatment Markets
Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.Analysis Article • Mar 20
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have continued their recent momentum with a 33% gain in the last month...Analysis Article • Mar 16
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up...Analysis Article • Jan 22
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Analysis Article • Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Analysis Article • Aug 02
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders are no doubt pleased to see that the share price has bounced 34...Shareholder Returns
| AKBA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.7% | -1.6% | -0.8% |
| 1Y | -64.0% | 34.4% | 27.1% |
Return vs Industry: AKBA underperformed the US Biotechs industry which returned 32.9% over the past year.
Return vs Market: AKBA underperformed the US Market which returned 26.7% over the past year.
Price Volatility
| AKBA volatility | |
|---|---|
| AKBA Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AKBA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AKBA's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 194 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
Akebia Therapeutics, Inc. Fundamentals Summary
| AKBA fundamental statistics | |
|---|---|
| Market cap | US$270.94m |
| Earnings (TTM) | -US$20.51m |
| Revenue (TTM) | US$232.40m |
1.2x
P/S Ratio-13.3x
P/E RatioIs AKBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBA income statement (TTM) | |
|---|---|
| Revenue | US$232.40m |
| Cost of Revenue | US$41.97m |
| Gross Profit | US$190.43m |
| Other Expenses | US$210.94m |
| Earnings | -US$20.51m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 81.94% |
| Net Profit Margin | -8.83% |
| Debt/Equity Ratio | 713.8% |
How did AKBA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 17:19 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akebia Therapeutics, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Michael King | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |